Cell & Gene Therapy

A proprietary vector discovery platform called Therapeutic Vector Evolution sits at the centre of 4DMT 's approach to genetic medicine. Rather than relying on existing delivery vehicles, the clinical-stage biopharma company engineers customised, proprietary gene delivery vectors matched to specific tissue types and routes of administration, with the goal of addressing large-market diseases where conventional treatments fall short. Founded in 2015 and headquartered in Emeryville, California, 4DMT trades on NASDAQ under the ticker FDMT. 4DMT's integrated product engine spans design, development and manufacturing, enabling the company to build a diverse clinical pipeline. Current therapeutic focus spans retinal diseases and pulmonary diseases, two areas with significant unmet need in which precision gene delivery to targeted tissue is critical. The company positions its work as striving for potential curative outcomes rather than symptomatic management, reflecting its stated ambition to unlock the full potential of genetic medicine. As a clinical-stage organisation, 4DMT combines platform innovation with pipeline execution, maintaining a scientific advisory structure that includes a dedicated Retina Advisory Board alongside broader scientific and corporate advisory boards. The company also supports internal diversity through its 4Diversity programme, which shapes workforce culture and recruitment practices. Further information is available at 4dmoleculartherapeutics.com.

ABL specialises in the development and manufacture of advanced biological therapeutics, with a particular focus on gene therapies, vaccines, oncolytics and immunotherapies . Working exclusively with client programmes rather than proprietary pipelines, the company positions itself as a dedicated development partner for organisations tackling some of the most complex disease areas in modern medicine. The company's manufacturing capabilities span virus manufacturing and process development, aseptic fill finish, and cell and virus banking. These services are supported by biologics and quality control testing, giving clients access to an integrated development pathway under a single provider. ABL also supplies ELISA kits as commercial products, reflecting a broader engagement with laboratory and analytical workflows. Government partnering is listed as a distinct service category, indicating that ABL works with public-sector and defence-adjacent clients in addition to commercial biotechnology and pharmaceutical sponsors. This positions the company within the wider landscape of biodefence and public health preparedness, alongside conventional clinical-stage biologics work. The organisation operates under the ABL, Inc. legal identity and maintains multiple locations, supporting projects across process development, manufacturing scale-up, and aseptic production. Its integrated service model is suited to sponsors requiring continuity across early development and late-stage manufacturing without transferring programmes between providers. Further information is available at ablinc.com.

Adaptimmune is built around a singular conviction: that engineered T-cells can be directed to fight cancer with precision and durability. The clinical-stage biopharmaceutical company focuses exclusively on cancer immunotherapy , developing cell therapies designed to arm a patient's own immune system against malignant disease. The company's pipeline has centred on next-generation T-cell receptor (TCR) therapies. Its named programmes include TECELRA, lete-cel, afami-cel, and uza-cel, all of which have been the subject of significant corporate activity. Adaptimmune announced the sale of these four cell therapies to US WorldMeds, a transaction that marks a strategic inflection point for the organisation and underscores the commercial value of its therapeutic assets. Trading on the Nasdaq under the ticker ADAPY, Adaptimmune has operated as a publicly listed entity, giving investors and industry partners visibility into its governance, pipeline progress and financial position. Its focus on T-cell receptor therapy places it within a specialised and competitive segment of oncology drug development, where target specificity and manufacturing scalability remain defining challenges. As a clinical-stage business, Adaptimmune's work sits at the intersection of translational science and commercial development, with programmes advancing from research through to patient-facing trials. The company publishes its pipeline status and scientific findings openly, providing industry professionals and research partners with access to its methodology and clinical data. Further information is available at adaptimmune.com.

Trusted by the cell and gene therapy sector since 2006, Akron Biotech supplies the ancillary materials that underpin advanced therapeutic manufacturing. Operating under the Akron Bio brand, the company occupies a specialised position in the biotech supply chain, providing the raw materials and contract services that research teams and commercial manufacturers depend on at every stage of development and scale-up. The product portfolio centres on three core categories: cytokines and growth factors , human plasma derived products, and media and media supplements. These materials are critical inputs for cell expansion, gene vector production, and the broader biomanufacturing workflows associated with advanced therapies. Alongside its catalogue offering, Akron Biotech runs dedicated manufacturing services covering proteins, media and buffers, and transfection and transduction reagents, giving clients a single source for both off-the-shelf supply and custom-manufactured components. Quality assurance is presented as a defining characteristic of the business. The company maintains regulatory support documentation and certificates for its materials, reflecting the compliance requirements of partners working in regulated therapeutic development environments. A knowledge centre comprising published posters, publications, and event resources further supports the scientific community using its products. Partnerships and collaborations form part of the company's stated commercial model, positioning Akron Biotech as an integrated supplier rather than a transactional vendor. Its leadership and newsroom functions suggest an active presence in the cell and gene therapy market rather than a passive catalogue role. Further information is available at akronbiotech.com.

Rooted in decades of albumin science first pioneered at Delta Biotechnology and later advanced under Novozymes Biopharma, Albumedix is a Nottingham-based biotechnology company that produces recombinant human serum albumin for pharmaceutical and bioprocessing applications. The company emerged as an independent entity following Novozymes' divestment of its biopharma operations, carrying forward a well-established manufacturing and regulatory heritage. Its flagship material, Recombumin, is expressed in Saccharomyces cerevisiae yeast and is entirely free of animal-derived and plasma-derived components. This origin gives manufacturers a consistent, traceable alternative to plasma-sourced albumin, addressing both supply-chain risk and evolving regulatory expectations around animal-free raw materials in biopharmaceutical production. Applications Across Biologics Manufacturing Albumin-based excipients supplied by Albumedix are used as stabilisers in vaccines, cell and gene therapy products, and protein biologics, where formulation integrity directly affects product shelf life and clinical performance. Beyond final-product formulation, Recombumin is also incorporated into cell culture media and bioprocessing workflows, supporting the growth of sensitive mammalian cell lines used in biologics development. The company operates under pharmaceutical-grade quality systems, with its materials referenced in regulatory dossiers for licensed medicines across multiple markets. Albumedix works with global pharmaceutical manufacturers, contract development and manufacturing organisations, and advanced therapy developers seeking compliant, well-characterised albumin raw materials. Further information is available at albumedix.com.

Europe's pioneer in integrated therapies for rare diseases and critical care, AOP Health (trading as AOP Orphan) brings together scientific rigour, clinical development and commercial delivery under one roof. The company operates at the intersection of rare disease medicine and intensive-care medicine, two areas where unmet patient need remains exceptionally high. The therapeutic focus spans cardiology and pulmonology, haemato-oncology, critical care, and advanced therapies. This breadth reflects a deliberate strategy to address conditions that are either underserved by mainstream pharmaceutical investment or require highly specialised clinical management. A patient story programme, including accounts of sepsis survival, illustrates the real-world impact the company seeks to communicate to partners, prescribers and policymakers alike. On the scientific side, AOP Health maintains an active clinical pipeline with new trials entering development, including a study of a novel treatment approach for blood cancers announced in June 2026. The company publishes its research findings and makes its innovation methodology available to industry audiences, reflecting an openness to scientific dialogue that is characteristic of organisations working in rare-disease areas subject to close regulatory scrutiny. AOP Health operates across multiple international locations and participates actively in the global congress calendar, including rare skin disease and haemato-oncology meetings. In June 2026, the company received a Gold award at the WKO Export Awards, recognising its performance as an Austrian exporter with international reach. This recognition underlines its standing as a commercially active, internationally operating pharmaceutical business, not merely a research-stage organisation. Further information is available at aop-health.com.

Bayer is one of the oldest and most globally recognised life sciences companies in the world, founded in Barmen, Germany in 1863 and responsible for introducing aspirin to modern medicine. Today the company operates across more than 100 countries, employing tens of thousands of people and generating revenues in the tens of billions of euros annually, with its shares listed on the Frankfurt Stock Exchange under the ticker BAYN. Pharmaceuticals Division Bayer's pharmaceuticals business focuses on four core therapeutic areas: cardiovascular disease, oncology, gynaecology, and ophthalmology. The company's cardiovascular portfolio is among the most recognised in the industry, anchored by Xarelto (rivaroxaban), one of the world's most widely prescribed oral anticoagulants. In oncology, Bayer has built a substantial presence in targeted therapies, including treatments for renal cell carcinoma and thyroid cancer. The division also holds a strong position in women's health, with a broad contraception and fertility product range distributed globally. Crop Science & Consumer Health Beyond pharmaceuticals, Bayer operates one of the world's largest crop science divisions, a segment significantly expanded following the acquisition of Monsanto in 2018. This business covers herbicides, fungicides, insecticides, and seeds, making Bayer a central player in global agricultural supply chains. The company's consumer health division, which markets established brands in pain relief, dermatology, nutritional supplements, and allergy care, was partially divested through a strategic review, reflecting Bayer's continued focus on its prescription and crop science core. Bayer's research and development investment spans biologics, cell and gene therapy, and radiopharmaceuticals, with the company actively expanding its pipeline through both internal programmes and external partnerships and acquisitions. Its global headquarters remain in Leverkusen, Germany, where the company was formally established. Further information is available at bayer.com.

Biogen pioneered the neuroscience field as one of the world's oldest independent biotechnology companies, founded in 1978 by a group of distinguished scientists including Nobel laureate Walter Gilbert. Headquartered in Cambridge, Massachusetts, the company has spent nearly five decades focused almost exclusively on neurological and neurodegenerative diseases, a level of specialisation that sets it apart from diversified pharma peers. Neuroscience Focus and Key Therapy Areas Biogen's portfolio centres on multiple sclerosis , where it holds one of the broadest treatment ranges in the industry, spanning injectable, oral, and infusion therapies. The company also works in spinal muscular atrophy, Alzheimer's disease, Parkinson's disease, and rare neurological conditions. Its partnership with Eisai produced lecanemab (marketed as Leqembi), an Alzheimer's treatment that received traditional FDA approval in 2023, marking a significant moment in a field that had seen decades of clinical setbacks. Global Scale and Commercial Presence Listed on the Nasdaq under the ticker BIIB, Biogen operates across more than 30 countries, with commercial infrastructure spanning North America, Europe, and Asia Pacific. The company invests heavily in research and development as a proportion of revenue, consistent with its identity as a science-led organisation rather than a marketing-driven one. Its biosimilars division, built through a long-standing collaboration with Samsung Bioepis, gives Biogen a commercial presence in the cost-sensitive biologics market alongside its branded neurology pipeline. Biogen has also expanded into rare disease and neuropsychiatry, reflecting a strategic effort to broaden the neuroscience platform beyond multiple sclerosis as the MS market faces increasing genericisation. The company's gene therapy interests, including assets in-licensed and acquired over recent years, signal further ambition in treating diseases at the molecular level. For professionals in pharmaceutical, biotech, and medical research sectors, Biogen represents one of the most focused large-cap neuroscience organisations operating globally. Further information is available at biogen.com.

BioNTech became a household name after co-developing one of the world's first authorised mRNA COVID-19 vaccines, demonstrating at global scale that mRNA technology could be translated from research concept into a licensed medicine in record time. mRNA Platform and Oncology Pipeline Founded in 2008 and headquartered in Mainz, Germany, BioNTech was built on the scientific conviction that mRNA could be engineered to instruct the body's own cells to produce therapeutically relevant proteins. While the COVID-19 vaccine (developed with Pfizer under the Comirnaty brand) brought the company to international prominence, BioNTech's founding ambition was in oncology. The company operates one of the most advanced individualised cancer vaccine programmes in the industry, designing patient-specific neoantigen treatments intended to train the immune system to recognise and attack tumour cells. The broader pipeline spans several modalities, including cancer immunotherapies, next-generation mRNA vaccines for infectious diseases, and cell therapies. BioNTech has established partnerships with major pharmaceutical companies and academic institutions across Europe, North America, and Asia, with clinical operations and research sites in Germany, the United States, and the United Kingdom. Global Reach and Listed Status BioNTech is listed on the Nasdaq stock exchange under the ticker BNTX, having completed its initial public offering in October 2019. The company employs thousands of scientists, clinicians, and operational staff across its global network and maintains dedicated manufacturing facilities in Germany alongside contract manufacturing partnerships. Its African expansion programme, focused on building local mRNA manufacturing capacity, reflects a stated commitment to equitable vaccine access in lower-income markets. In the B2B context, BioNTech engages with contract manufacturers, clinical research organisations, regulatory consultancies, and supply chain partners across the full drug development and commercialisation lifecycle. Further information is available at biontech.com.

Boehringer Ingelheim ranks among the largest research-driven pharmaceutical companies in the world and, uniquely for a business of its scale, remains wholly family-owned, having operated independently since its founding in Ingelheim am Rhein, Germany, in 1885. That private ownership shapes everything from its long investment horizon to its willingness to pursue complex biology that publicly listed peers may avoid. Human and Animal Health The company operates across two distinct businesses. Its human pharma division concentrates on respiratory diseases , cardiovascular and metabolic conditions, oncology, and immunology, with established medicines spanning COPD, heart failure, type 2 diabetes, and idiopathic pulmonary fibrosis. The animal health division is one of the largest in the world, covering livestock and companion animal health across a broad portfolio of vaccines and therapeutics, a segment reinforced by the 2017 asset swap with Sanofi that brought in Merial. Global Research & Biopharmaceutical Manufacturing Boehringer Ingelheim maintains a significant contract manufacturing presence alongside its own pipeline work. Its biopharmaceutical contract manufacturing organisation arm, among the longest-established in the industry, produces biologics for third-party clients as well as internal programmes. Research centres span Germany, Austria, the United States, China, and other locations, with the company consistently investing a substantial proportion of net sales back into research and development each year. Its pipeline spans small molecules, biologics, and cell and gene therapy technologies, reflecting a deliberate push into next-generation modalities. The group employs tens of thousands of people across more than 130 markets globally. Headquartered in Ingelheim am Rhein, the company's independent status means it publishes net sales rather than stock-market results, with figures consistently placing it within the global top-ten pharmaceutical groups by revenue. Its therapy focus on diseases with significant unmet need, combined with a long-term ownership model, gives it a research culture oriented toward decade-spanning programmes rather than quarterly targets. Further information is available at boehringer-ingelheim.com.

Bristol Myers Squibb has built its modern identity around a singular strategic conviction: that understanding the biology of serious disease at the molecular level is the fastest route to transformative medicines. The company traces its origins to 1887, and its current form emerged from the merger of Bristol-Myers and Squibb in 1989, creating one of the world's largest research-driven biopharmaceutical companies. It is listed on the New York Stock Exchange under the ticker BMY. Oncology & Immuno-Oncology Leadership The area where BMS has most visibly reshaped clinical practice is oncology , and specifically immuno-oncology. Opdivo (nivolumab) and Yervoy (ipilimumab) are among the most widely recognised checkpoint inhibitors in global oncology, having been approved across a broad range of tumour types. The company's acquisition of Celgene in 2019, one of the largest transactions in pharmaceutical history at the time, added Revlimid and a substantial haematology portfolio, reinforcing BMS's position in multiple myeloma and other blood cancers. Cardiovascular & Immunology Pipeline Beyond oncology, BMS has longstanding expertise in cardiovascular disease , with Eliquis (apixaban), developed in partnership with Pfizer, becoming one of the most prescribed oral anticoagulants worldwide. The immunology and fibrosis franchises have grown in strategic importance, with the company investing in targeted protein degradation and cell therapy as emerging modalities. CAR T platforms, brought in through the Celgene acquisition, represent a key area of next-generation oncology development. Headquartered in Princeton, New Jersey, BMS operates across more than 40 countries, with major research campuses in the United States and Europe. The company employs tens of thousands of people globally and maintains a significant presence in clinical development, running one of the pharmaceutical industry's larger late-stage trial portfolios at any given time. Its commercial and scientific scale, combined with a focused therapeutic strategy centred on serious diseases with high unmet need, places BMS among a small number of companies that consistently shape oncology, haematology and cardiovascular treatment standards worldwide. Further information is available at bms.com.

Catalent is one of the world's largest contract development and manufacturing organisations, supplying drug substance, drug product, and biologics capabilities to pharmaceutical and biotechnology companies across more than 40 countries. Founded in 2007 following the spin-off of Cardinal Health's pharmaceutical technologies and services division, the company built its reputation on solving formulation and delivery challenges that its clients cannot address in-house. Drug Delivery Technologies Catalent's portfolio of proprietary drug delivery platforms is a primary reason manufacturers turn to the company at early development stages. Its Softgel and Optiform technologies serve both small-molecule and biologics formulations, while the OptiMelt and Zydis orally disintegrating tablet platforms address specific bioavailability and patient-compliance challenges. These platforms are applied across therapeutic areas including oncology, rare diseases, consumer health, and central nervous system indications. Biologics & Gene Therapy Manufacturing In recent years, Catalent significantly expanded its biologics manufacturing capacity through a series of acquisitions and facility investments, most notably its purchase of the Bloomington, Indiana biologics site and the acquisition of Paragon Bioservices, which brought substantial cell and gene therapy manufacturing capability. The Harmans, Maryland gene therapy facility became one of the largest commercial-scale viral vector manufacturing sites in North America. This expansion positioned Catalent as a significant partner for advanced therapy developers requiring specialist fill-finish, cell culture, and analytical services. Catalent operates across the United States, Europe, and the Asia-Pacific region, with major sites in Somerset (New Jersey), Brussels, Swindon, and Sydney among others. The company was publicly traded on the New York Stock Exchange under the ticker CTLT before Novo Holdings announced its acquisition in 2024, subsequently transferring a number of its biologics manufacturing sites to Novo Nordisk as part of that transaction. The company serves customers ranging from the world's leading pharmaceutical groups to emerging biotech companies seeking development-stage formulation support through to commercial-scale supply. Further information is available at catalent.com.